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bjectives We sought to determine safety, recurrence rates, and novel risk factors for recurrence in
atients with cryptogenic stroke/transient ischemic attack (TIA) after patent foramen ovale closure.
ackground Patent foramen ovale closure in patients with cryptogenic stroke/TIA remains highly con-
roversial. There are limited data on long-term recurrence rates and their predictors in these patients.
ethods The records of all patients who underwent patent foramen ovale device closure between
ecember 2001 and June 2006 were reviewed. Patients were seen for clinical follow-up at 3 months
hen followed annually via telephone. Primary end points were recurrent stroke/TIA. Kaplan-Meier
ethods were used to estimate recurrent event rates. Cox regression analysis was used to identify
isk factors for recurrences.
esults There were 352 patients with cryptogenic stroke (n  225) or TIA (n  118) with a mean
ge of 53.4 years. The procedural complication rate was 3.4%. Recurrent events occurred in 8 pa-
ients: 7 strokes and 2 TIA, 1 patient had 2 recurrent strokes. The recurrence rate was 0.6% and 2.1%
or stroke and 0.3% and 0.7% for TIA at 1 and 4 years, respectively. The combined end point of re-
urrent stroke/TIA occurred at a rate of 0.9% and 2.8% at 1 and 4 years, respectively. Risk factors for
ecurrences were elevated pulmonary artery pressure (hazard ratio [HR]: 1.12, p  0.009), elevated
ight ventricular pressure (HR: 1.09, p  0.04), factor V Leiden mutation (HR: 7.42, p  0.014), and
rotein S deﬁciency (HR: 12.2, p  0.002). Residual shunt and atrial septal aneurysm were not asso-
iated with recurrences.
onclusions Patent foramen ovale device closure is safe and is associated with a low recurrence of
troke/TIA. Factors associated with recurrence are thrombophilia and elevated intracardiac pressures.
J Am Coll Cardiol Intv 2009;2:404–11) © 2009 by the American College of Cardiology Foundation
rom the Divisions of *Cardiovascular Diseases, †Biostatistics, ‡Neurology, and §Pediatric Cardiology, Mayo Clinic College of
edicine, Rochester, Minnesota. Funded by the Division of Cardiovascular Diseases, Mayo Clinic Rochester, Minnesota.anuscript received December 9, 2008, accepted December 21, 2008.
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405troke remains the third leading cause of death, and in
004, caused 1 of every 16 deaths in the U.S. Cryptogenic
trokes comprise between 20% and 40% of ischemic strokes
1). In the Rochester Epidemiology Project, the total age-
nd sex-adjusted incidence rate for cryptogenic ischemic
troke subtypes was 52 per 100,000 population (2). Patent
oramen ovale (PFO) is detected in up to 24% in healthy
ndividuals on transesophageal echocardiography (TEE)
tudies (3). The prevalence of PFO in patients with cryp-
ogenic stroke is significantly higher, with estimates ranging
rom 30% up to 70% (4–7), suggesting an etiologic role.
See page 412
Direct documentation of embolization through a patent
FO is rare (8–10) so there remains considerable debate
bout the role of PFO in stroke/transient ischemic attack
TIA). Although several studies established strong associa-
ions between the PFO and cryptogenic stroke/TIA
5,6,11–13), not all (14,15) substantiate this association.
There has been dramatic increase in percutaneous PFO
losure in recent years (16), but there are at present no data
rom randomized trials in this field. However, observational
ata show reduced episodes of cryptogenic stroke/TIA after
FO closure (17–19). The objectives of the present study
ere to systematically review our experience with transcath-
ter device closure of PFO in selected patients with cryp-
ogenic stroke/TIA with regard to procedural safety and
fficacy, measure recurrent event rates, and identify risk
actors for these recurrent events.
ethods
e reviewed the Mayo Clinic Rochester PFO database for
atients who underwent percutaneous device closure of
FO for cryptogenic stroke/TIA between December 2001
nd June 2006. Patients were referred from external insti-
utions or internal referrals from neurologists and other
olleagues. Baseline characteristics, procedural details, com-
lications, and follow-up data were reviewed for all patients.
atients were included only if their qualifying neurologic
vent was a documented ischemic stroke or TIA. All
atients gave written informed consent for inclusion in the
tudy, and the Mayo Foundation Institutional Review
oard approved the study.
eﬁnitions. Patent foramen ovale was defined as the pres-
nce of a typical flaplike interatrial communication with
nteratrial shunting during echocardiography detected by
olor flow imaging or intravenous injections of agitated
aline at rest or with provocative maneuvers such as cough or
alsalva (14). Right-to-left atrial shunting was diagnosed if
icro bubbles were observed to cross the defect into the left jtrium within 3 to 5 cardiac cycles after injection (3). Atrial
eptal aneurysm (ASA) was diagnosed if part or all of the
trial septum exhibited aneurysmal dilation protruding at
east 1.5 cm beyond the plane of the atrial septum or if there
as phasic excursion during the cardiorespiratory cycle
xceeding 1.5 cm and if the base of the aneurysmal protru-
ion was at least 1.5 cm in diameter (20).
We defined ischemic stroke as the acute onset (minutes to
ours) of a focal neurologic deficit persisting more than
4 h, with computed tomography (CT) or magnetic reso-
ance imaging (MRI) documentation and caused by altered
irculation to a limited region of the cerebral hemispheres,
rainstem, or cerebellum. Patients were excluded if findings
n CT or MRI showed evidence of intracerebral hemor-
hage or some other nonischemic cause for the presenting
ymptoms. Transient ischemic attack was defined as a
eurologic deficit lasting 24 h attributed to focal cerebral
schemia (21). We used the TOAST (Trial of Org 10172 in
cute Stroke Treatment) defini-
ion for cryptogenic stroke as the
resence of a stroke in a patient
ith no likely etiology determined
espite an extensive evaluation
22). We excluded patients whose
ualifying event was peripheral
mbolization such as renal or ret-
nal emboli as their only embolic
vent.
re-procedure evaluation. All
atients underwent comprehen-
ive neurology evaluation by a
eurologist. A diagnosis of cryp-
ogenic stroke or TIA was made
nly after extensive evaluation
xcluded any secondary causes.
atients underwent neurology
onsultation with imaging: brain CT and/or MRI. Some
atients had additional imaging including magnetic reso-
ance angiography of the head and neck or cerebral angiog-
aphy. Patients also underwent thrombophilia screens with
ematology consultations for any abnormal findings and
ardiac Holter monitoring to screen for cardiac arrhythmias.
All patients had transthoracic echocardiography (TTE)
nd TEE with color Doppler flow and agitated saline
ontrast at rest and with Valsalva maneuver for identifica-
ion of PFO and right-to-left shunting. Patients were not
xcluded based on resting PFO size or degree of shunting as
ong as some right-to-left shunt was observed. Patients with
n identified cause of stroke such as intracardiac thrombus,
egetation, significant carotid or vertebral artery abnormal-
ty, or other embolic source were excluded. The clinical
ecision to proceed with PFO closure was made in con-
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
CT  computed tomography
IQR  interquartile range
MRI  magnetic resonance
imaging
PFO  patent foramen ovale
TEE  transesophageal
echocardiography
TIA  transient ischemic
attack
TTE  transthoracic
echocardiographyunction with the neurologist involved in the patient’s care.
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406mplantation procedure. We previously described the pro-
edure of percutaneous PFO device closure (23). Briefly,
atients presented to the cardiac catheterization laboratory
fter an overnight fast. Femoral venous sheaths were placed
nd intravenous heparin was administered. Hemodynamic
ight heart catheterization was performed. Under TEE (n
0) or intracardiac echocardiographic (n  292) guidance,
he PFO was visualized. The stretched PFO diameter was
hen measured using a low pressure, compliant sizing
alloon to facilitate appropriate device sizing.
Patients received either the Amplatzer ASD (AGA
edical Corporation, Plymouth, Minnesota) or the Cardio-
EAL (NMT Medical Inc., Boston, Massachusetts) septal
ccluder device. If device placement was judged suboptimal,
he device was withdrawn and repositioned or a new device
as placed. Patients were observed in hospital overnight and
ismissed the following day after a TTE demonstrated
ormal device position and no pericardial effusion. All
atients received aspirin 81 to 325 mg after the procedure.
t the discretion of the operator, some patients received
lopidogrel 75 mg for 1 month after the procedure. War-
arin was usually not used unless there was an indication for
nticoagulation such as in those patients with thrombophilia
ho received warfarin for 6 months after device closure.
ollow-up evaluation. Patients returned for follow-up at
pproximately 3 months after the procedure and underwent
limited history, examination, and TTE with agitated
aline contrast, at rest and with the Valsalva maneuver, to
etermine presence of any residual shunt. All patients were
hen called yearly to complete a standardized telephone
uestionnaire (Online Appendix) for surveillance of recur-
ent events. Patients were followed at other junctures at the
iscretion of their primary providers. All subsequent echo-
ardiograms performed at our institution for follow-up of
ersistent shunts or for other indications were also reviewed.
valuation of recurrent events. Patients were evaluated for
he occurrence of the pre-specified primary end points of
ecurrent stroke and/or TIA. Pertinent external clinical
ecords were obtained for the adjudication process as nec-
ssary. All post-procedure events were audited by the author
anel by review of hospital and clinical records. Question-
ble events were adjudicated by a neurologist (R.D.B. and
.W.P.) who reviewed clinical records and neurologic
maging (brain CT or MRI). Only definite recurrent strokes
nd TIA were included in the analysis. All patients with
ecurrent events also underwent TTE or TEE to check for
cardiac source of embolism, device position, or residual
hunt.
tatistical analysis. Continuous variables were expressed as
ean  SD unless otherwise indicated. Discrete variables
re summarized as frequency and percentage. Survival esti-
ates, such as recurrent thromboembolic events during
ollow-up were calculated using Kaplan-Meier methods.
ox regression analysis was used to calculate hazard ratios pnd identify risk factors for recurrent events. We considered
values 0.05 to be statistically significant.
esults
etween December 2001 and June 2006, 441 patients at
ayo Clinic Rochester underwent percutaneous transcath-
ter device closure of PFO for events presumed secondary to
aradoxical embolization. Thirty-eight patients did not give
onsent for review of their records so were not included; 51
atients were excluded because their qualifying event was
ot stroke or TIA. The study population consisted of the
emaining 352 patients.
aseline characteristics. There were 208 males and 144
emales (Table 1). The mean age of the population was 53.4
ears (median: 54 years, range: 19 to 84 years). There were
25 patients (63.9%) who had stroke, 118 patients (33.5%)
ith TIA, and 9 patients with both as their qualifying event.
ourteen patients had a history of peripheral embolism
long with their qualifying stroke or TIA. All patients had
chocardiographic right-to-left shunt, either at rest or after
alsalva release. Atrial septal aneurysm was diagnosed in 83
23.6%) of patients. None were noted to contain thrombus.
rocedural results. The mean intracardiac pressures are
hown in Table 1. The mean unstretched PFO size was 5.8
3.4 mm, and the mean stretched diameter at procedure
as 11.3  3.8 mm. We successfully deployed 352 devices
100% procedural success). Procedural success was defined
s deployment of a device with disks on either side of the
FO flap with no or minimal residual shunt without
mpingement of adjacent cardiac structures. An Amplatzer
eptal occluder device was used in 348 of the 352 procedures
nd a CardioSEAL occluder was deployed in 4 patients.
he mean device size was 14.1  4.2 mm.
Procedural complications were defined as those occurring
uring the PFO procedure and up to the patient’s dismissal
rom hospital, usually within 24 h. Complications occurred
n 12 patients: 7 males and 5 females (3.4%) and included
trial flutter (n  2), atrial fibrillation, protamine reaction,
asovagal reaction, retroperitoneal bleed, pericardial tam-
onade, transient diplopia, vascular complications, and tran-
ient generalized erythema. Development of complications
as not related to age or gender. There were no procedural
eaths and no patient required a surgical procedure.
ollow-up. The mean follow-up was 37 months (interquar-
ile range [IQR]: 25 to 49 months) with a maximum follow
p of 6 years. Of the total study population, 89% were
ontacted within 1 year of retrieval of the follow-up data,
5% were contacted within 18 months, and 98% within 2
ears.
esidual shunt. At the first post-discharge echocardio-
ram (median duration from closure: 98 days, IQR: 86 to
20 days), residual shunt was detected in 21 (6.6%)
atients. At the last follow-up echo (median duration
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407rom closure: 129 days, IQR: 92 to 472 days), residual
hunt remained in 15 (4.3%). Overall, residual shunt was
resent at any time during follow-up in 27 (8.5%) patients.
ollow up shunt data was not available in 34 patients. None
f the patients with residual shunts at last follow-up had
ecurrent events.
eaths. There were 16 deaths during follow-up, none of
hich were due to device complications or recurrent neu-
ological ischemic events (Table 2).
nticoagulant use. Follow-up medication data was available
Table 1. Baseline Characteristics (N  352)
Mean age, yrs 53.4 (19.0–84.0)
Male 208 (59.1)
Female 144 (40.9)
Aspirin 252 (72)
Clopidogrel 80 (22.8)
Warfarin 157 (44.7)
HTN 130 (36.9)
Diabetes mellitus 25 (7.1)
Oral contraceptives 15 (4.3)
Hyperlipidemia 146 (41.6)
Smoking
Current 31 (8.8)
Former 80 (24)
Atrial septal aneurysm 83 (23.6)
Intracardiac thrombus 0
Baseline right-to-left shunt grade
Minimal 86 (36.4)
Moderate 107 (45.3)
Severe 41 (17.4)
Coagulation screen 293 (89.6)
Protein C deﬁciency 14 (4.3)
Protein S deﬁciency 11 (3.4)
Factor V Leiden 14 (4.3)
Lupus anticoagulant 3 (0.9)
Anticardiolipin antibodies 9 (2.8)
Brain computed tomography 152 (43.2)
Brain MRI 266 (75.6)
Cerebral angiogram 24 (6.8)
Carotid ultrasound 88 (25)
24-h Holter 129 (36.7)
Qualifying event
Stroke 234 (66.5)
TIA 127 (36.1)
Mean right atrial pressure, mm Hg 6 (0–20)
Mean left atrial pressure, mm Hg 9 (3–22)
Right ventricular systolic pressure 29 (20–52)
Pulmonary artery systolic pressure, mm Hg 27 (13–53)
Unstretched PFO diameter, mm 5.8 (1.0–16.0)
Stretched PFO diameter, mm 11.3 (3.0–22.0)
Variables expressed as mean (range) or n (%).
HTN  hypertension; MRI  magnetic resonance imaging; PFO patent foramen ovale; TIA 
transient ischemic attack.n 351 of 352 (99.7%) cases. There were 145 (41%) patientsn warfarin, 117 (33%) on clopidogrel, and 327 (93%) who
ere on aspirin after the procedure.
ecurrent events. There were 8 recurrent events in 7 pa-
ients (2.3%). There were 7 strokes and 2 TIA with 1
atient having 2 recurrent strokes. There were no peripheral
mbolizations. The first recurrent stroke occurred 163 days
fter the procedure in a patient whose qualifying event was
troke. At the time of the recurrent event, TEE was
erformed in 6 patients and 1 patient had TTE. No
ntracardiac thrombus, device dislodgement, or residual
hunt was detected in any patient with a recurrent event.
wo patients had an event before their first follow-up. Of
he remaining 6 patients, 5 (83%) were on warfarin, 3 (50%)
ere on clopidogrel, and 5 (83%) were on aspirin after
evice closure and before their recurrent neurologic event.
The recurrence rate at 1 year was 0.6% for stroke and
.3% for TIA. At 4 years, the recurrence rate for stroke was
.1% and 0.7% for TIA (Figs. 1A and 1B). The recurrence
ate for the combined end point of recurrent stroke or TIA
as 0.9% at 1 year and 2.8% at 4 years (Fig. 1C). Although
here was a steady annual event rate, the overall risk during
ollow-up was very low. Using hazard ratio (HR) analysis,
actor V Leiden mutation (HR: 9.9, p  0.001), protein S
eficiency (HR: 3.1, p  0.014), and elevated pulmonary
rtery pressure (HR: 1.12, p  0.009) were statistically
ssociated with recurrent events (Table 3). Notably,
ecurrent events were not significantly related to initial
FO size, presence of ASA, or device type. No patient
ith a recurrent event had a residual shunt or intracardiac
r device thrombus.
Table 2. Patient Deaths During Follow-Up
Patient
#
Time Between
PFO Closure and
Death (days) Cause of Death
1 47 Acute renal failure, cardiogenic shock,
staphylococcal pneumonia
2 122 Right-sided congestive heart failure,
primary biliary cirrhosis
3 281 Squamous cell carcinoma of the ovary
4 654 Ventricular ﬁbrillation arrest
5 264 Acute coronary syndrome
6 292 Acute respiratory distress syndrome
7 1,500 Esophageal and lung cancer
8 303 Liver cancer
9 269 Bladder cancer
10 549 Central nervous system lymphoma
11 24 Aspiration pneumonia
12 21 Bladder cancer
13 747 Myocardial infarction
14 33 Lung cancer
15 6 Died before consent to review records obtained16 148 Renal failure, idiopathic cardiomyopathy
DW
i
fi
a
c
p
T
v
s
a
r
C
c
c
t
r
e
h
p
R
p
T
H
o
e
e
m
p
d
(
t
d
b
e
c
c
r
t
w
A
f
i
m
f
(
h
i
w
b
w
lines represent 95% conﬁdence limits.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 5 , 2 0 0 9
M A Y 2 0 0 9 : 4 0 4 – 1 1
Ford et al.
PFO Device Closure for Cryptogenic Stroke/TIA
408iscussion
e reviewed our experience with percutaneous PFO closure
n 352 patients with cryptogenic stroke or TIA. The major
ndings of this study are: 1) PFO device closure is effective
nd safe with a complication rate of 3.4% with no compli-
ations causing long-term deficits or death; 2) a small
roportion of patients (2.3%) have recurrent events (stroke/
IA) after PFO closure; 3) the recurrent stroke/TIA rate is
ery low; 4) thrombophilia and elevated pulmonary pres-
ures increase the risk of recurrent thromboembolic events;
nd 5) neither ASA nor residual shunt was associated with
ecurrent events.
omplications. Our complication rate was 3.4%, which is
onsiderably lower than previously reported (23), and most
omplications were minor. The only serious complication,
amponade, occurred in 1 patient and was immediately
ecognized and treated with pericardiocentesis in the cath-
terization laboratory and did not recur. Wahl et al. (24)
ad a complication rate of 2.5% in over 500 consecutive
atients.
ecurrent events. The rates of recurrent events in our study
opulation are lower than the rates of recurrent stroke and
IA in general population studies of stroke patients. In the
eart Disease and Stroke Statistics 2007 Update (25), 13%
f men and 22% of women between 40 to 69 years
xperience a recurrent stroke within 5 years of the first
vent, whereas in patients age 70 years and older, 23% of
en and 28% of women have recurrent strokes.
It is exceedingly difficult to identify a control group of
atients with PFO and recurrent cryptogenic strokes who
o not undergo intervention. Results of 2 systematic reviews
17,18) encompassing 21 publications of medical or catheter
herapy for PFO are shown in Table 4. These observational
ata, overlapping to some extent, summarize the knowledge
ase from 1985 to 2005 regarding secondary prevention of
mbolic events with either medical therapy or catheter
losure. Although outcomes are reported differently, figures
an be considered roughly equivalent to a 1-year risk of
ecurrent event. Our recurrence rates for stroke or TIA of less
han 1% at 1 year are significantly lower than those associated
ith medical therapy in these studies (3.8% to 12%).
trial septal aneurysm. Atrial septal aneurysm was not a risk
actor for recurrence in this study but has been suggested to
ncrease the risk of stroke in patients with PFO. In a
eta-analysis by Overell et al. (12), the odds ratio was 4.96
or PFO with ASA versus 1.83 for PFO only. Cabanes et al.
26) reported a relative risk of cryptogenic stroke 33 times
igher than controls for both PFO and ASA versus a 4-fold
ncrease with PFO only. In a study by Mas et al. (7), there
as a 4-fold higher risk of recurrent stroke in patients with
oth PFO and ASA than in those patients with no defect orFigure 1. Recurrent Stroke/TIA After PFO Device Closure
(A) Recurrent stroke after patent foramen ovale (PFO) device closure was 0.6%
at 1 year and 2.1% at 4 years. (B) The rate of recurrent transient ischemic
attack (TIA) after percutaneous device PFO closure was 0.3% at 1 year and
0.7% at 4 years. (C) The rate of the combined end point of recurrent ischemic
stroke/TIA after PFO closure was 0.9% at 1 year and 2.8% at 4 years. Dashedith PFO alone. Other studies have not shown such an
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409ssociation (18,19,27). One proposed mechanism by which
SA could increase stroke risk is by in situ thrombosis. We
id not observe thrombus in any of the 83 patients with
SA. In addition, the constant mobility of the ASA
bserved by echocardiography would reduce the likelihood
f development of in situ thrombosis.
esidual shunt. Unlike other published reports (19), we
id not find residual shunts in any patient who had a
ecurrent event. In fact, 90% of residual shunts detected
y contrast echocardiography at the first 3-month
ollow-up visit spontaneously closed by 255 days after the
rocedure. Most shunts were tiny and often only noted
Table 3. Risk Factors for Recurrent Stroke/TIA After PFO Device Closure
Variable
No Event
(n  344)
Age, yrs 53.3  13.2
Male 203 (59)
Aspirin 248 (73)
Clopidogrel 77 (22)
Warfarin 154 (45)
Hypertension 125 (36%)
Hyperlipidemia 141 (41)
Diabetes mellitus 24 (7)
Oral contraceptives 15 (4)
Smoking status
Former 76 (23)
Current 17 (5)
Atrial septal aneurysm 81 (27)
Normal coagulation screen 288 (90)
Protein C deﬁciency 13 (4)
Protein S deﬁciency 9 (3)
Factor V Leiden 12 (4)
Lupus anticoagulant 3 (1)
Anticardiolipin antibodies 9 (3)
Mean right atrial pressure, mm Hg 6.2  3.3
Mean left atrial pressure, mm Hg 8.7  3.5
Right ventricular systolic pressure, mm Hg 28.4  7.7
Pulmonary artery pressure, mm Hg 26.9  6.4
Pulmonary capillary wedge pressure, mm Hg 9.7  4.2
Stretched PFO diameter, mm 11.0  3.7
Device size 14.1  4.2
Bold values are statistically significant.
CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.
Table 4. Secondary Prevention of Cryptogenic Stroke With PFO: Results of
Investigator (Ref. #) Years Therapy N
Homma et al. (15)* 1990–2005 Medical 9
Catheter closure 1,4
Khairy et al. (18)† 1985–2003 Medical 8
Catheter closure 1,3
*Events reported as percentage per 100 patient-years (15). †Events reported as percentage of recuAbbreviations as in Table 1.ith Valsalva release. We do not recommend aggressive
ttempts to obliterate tiny residual shunts detected at
arly follow-up with additional device deployment be-
ause they often close spontaneously without affecting
utcome. The lack of association of residual shunt with
ecurrent events is puzzling. It could be postulated that
ncomplete endothelialization of the Amplatzer device
ould allow some tiny residual intradevice bubble shunt-
ng while preventing paradoxical embolization of larger
hrombi. Alternatively, neurologic events at follow-up
and including the index event) may represent, in some
atients, a process totally unrelated to the PFO.
Event
(n  8) HR (95% CI) p Value
57.0  18.7 1.02 (0.97–1.08) 0.43
5 (63) 1.15 (0.27–4.80) 0.85
4 (50) 0.36 (0.09–1.43) 0.15
3 (38) 2.02 (0.48–8.44) 0.34
3 (38) 0.67 (0.16–2.84) 0.59
5 (63) 3.00 (0.72–12.5) 0.13
5 (50) 1.43 (0.41–4.95) 0.57
1 (13) 2.33 (0.28–19.0) 0.43
0 0.99
2 (25) 0.94 (0.19–4.64) 0.64
0
2 (25) 0.96 (0.19–4.76) 0.96
5 (63) 0.19 (0.05–0.81) 0.025
1 (13) 3.11 (0.38–25.3) 0.29
2 (25) 12.2 (2.42–61.1) 0.002
2 (25) 7.42 (1.49–36.8) 0.014
0 0.99
0 1.00
7.5  2.4 1.11 (0.90–1.37) 0.34
12.3  6.0 1.27 (0.95–1.69) 0.10
34.1  5.8 1.09 (1.00–1.19) 0.048
33.4  5.4 1.12 (1.03–1.22) 0.009
11.7  4.9 1.09 (0.94–1.26) 0.25
13.2  3.8 1.16 (0.95–1.41) 0.15
14.8  3.9 1.04 (0.88–1.22) 0.66
tematic Reviews From 1985 to 2003
Stroke (%) TIA (%) Stroke/TIA (%)
1.98 2.24 4.22
0.19 1.52 1.62
— — 3.8–12
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410hrombophilia and recurrent events. Five patients with
ecurrent events had a thrombophilia: heterozygous factor V
eiden (n  2), protein C deficiency (n  1), and protein
deficiency (n  2). The presence of factor V Leiden
utation or protein S deficiency imparted a significant risk
f recurrent stroke/TIA (HR: 7.4 and 12.2, respectively).
In patients with PFO, thrombophilic states may increase
he occurrence of venous clots that can paradoxically embo-
ize to the systemic circulation. In fact, in a recent case-
ontrol matched study, thrombophilia predisposed patients
ith PFO to cryptogenic strokes (HR: 2.8) (28). Based on
hese observations, we would recommend that patients with
FO and thrombophilias be strongly considered for chronic
ral anticoagulation after device closure. Further studies are
eeded to extend this recommendation for primary stroke
rophylaxis in such patients. However, after PFO closure,
he mechanism would be less clear but may include device or
n situ thrombosis. We did not observe device thrombus in
atients with recurrent events in this study but not all
atients had TEE performed.
ntracardiac pressures and recurrent events. Patients with
ecurrent stroke/TIA had higher mean intracardiac pres-
ures than those who did not have recurrent events even
hough pressures were still within the normal range (Table
). Patients with elevated right-sided pressures have a
igher right-to-left pressure gradient, which, under the
ight circumstances, could facilitate systemic embolization.
everal investigators have described strokes occurring dur-
ng Valsalva maneuvers (29). Perhaps higher pressure is a
arker of increased stroke risk by association with factors
uch as diastolic dysfunction rather than being a direct
ausal factor. However, in the entire study population, the
ight-sided pressures were only minimally elevated (mean
ight atrial pressure: 6.2  3.3 mm Hg, mean right
entricular systolic pressure: 28.4  7.7 mm Hg, mean
ulmonary artery systolic pressure: 26.9  6.4 mm Hg) so
he clinical significance of this finding is unclear.
tudy limitations. The retrospective nonrandomized nature
f this highly selected study population may not be repre-
entative of the general population at risk. The small
umbers of recurrent events make it difficult to absolutely
efine the true treatment effect of PFO device closure.
linically silent cerebral ischemic episodes would not have
een detected. Exhaustive efforts were taken to exclude
atients with strokes from other identifiable causes, and we
elieve our study population is a good representation of truly
ryptogenic stroke/TIA patients. The likelihood of ascer-
ainment bias with unreported recurrent events is low
ecause all patients had complete and extensive follow-up.
he absence of a similarly selected control population
patients presenting to our institution with cryptogenic
troke with PFO without closure during this time frame) is
major limitation. Ongoing randomized trials will provideuch a group and hopefully a similar cohort of cryptogenic
troke patients will be enrolled.
Percutaneous device closure of PFO in patients with
ryptogenic stroke or TIA is safe with a 3.4% procedural
omplication rate at our institution. The combined recur-
ence rate of stroke/TIA was 0.9% at 1 year and 2.8% at 4
ears. Thrombophilia and increased intracardiac pressures
ere risk factors for recurrent events after PFO device
losure. We found no association between recurrent events
nd residual shunting or ASA. The majority of residual
hunts spontaneously close within a year. We await the
esults of randomized clinical trials to accurately quantify
he effect of PFO device closure on recurrent cryptogenic
trokes/TIA as compared with medical therapy. Until such
rials are completed, we believe our results support PFO
losure for cryptogenic stroke in carefully selected patients.
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APPENDIX
or the text of the phone follow-up and the written questionnaire, please
ee the online version of this article.
